| | | Page | | |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | 43 | | | |
| | | | 57 | | | |
| | | | A-1 | | |
Proposal | | | Vote Required | | | Broker Discretionary Voting Allowed | |
Proposal 1 | | | Majority of the votes cast | | | No | |
Proposal 2 | | | Majority of the voting power of the shares present virtually or represented by proxy and entitled to vote on the subject matter | | | Yes | |
Proposal 3 | | | Majority of the voting power of the shares present virtually or represented by proxy and entitled to vote on the subject matter | | | No | |
Proposal 4 — Advisory Vote on the Frequency of the Advisory Vote to Approve Executive Compensation | | | The alternative among “ONE YEAR,” “TWO YEARS” or “THREE YEARS” that receives the plurality of votes cast | | | No | |
Proposal 5 — Advisory Vote Regarding Retention of the Classified Board of Directors | | | Majority of the voting power of the shares present virtually or represented by proxy and entitled to vote on the subject matter | | | No | |
Board Diversity Matrix (As of April 14, 2022) | | ||||||||||||||||||||||||
| | ||||||||||||||||||||||||
Total Number of Directors | | | 9 | | |||||||||||||||||||||
| | | Female | | | Male | | | Non- Binary | | | Did Not Disclose Gender | | ||||||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
Directors | | | | | 3 | | | | | | 6 | | | | | | 0 | | | | | | 0 | | |
Part II: Demographic Background | | | | | | | | | | | | | | | | | | | | | | | | | |
African American or Black | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Alaskan Native or Native American | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Asian | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Hispanic or Latinx | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Native Hawaiian or Pacific Islander | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
White | | | | | 2 | | | | | | 6 | | | | | | 0 | | | | | | 0 | | |
Two or More Races or Ethnicities | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
LGBTQ+ | | | 0 | | |||||||||||||||||||||
Did Not Disclose Demographic Background | | | 0 | |
Total Number of Directors | | | 9 | | |||||||||
| | | Female | | | Male | | | Non- Binary | | | Did Not Disclose Gender | |
Part I: Gender Identity | | | | | | | | | | | | | |
Directors | | | 3 | | | 6 | | | 0 | | | 0 | |
Part II: Demographic Background | | | | | | | | | | | | | |
African American or Black | | | 1 | | | 0 | | | 0 | | | 0 | |
Alaskan Native or Native American | | | 0 | | | 0 | | | 0 | | | 0 | |
Asian | | | 0 | | | 0 | | | 0 | | | 0 | |
Hispanic or Latinx | | | 0 | | | 0 | | | 0 | | | 0 | |
Native Hawaiian or Pacific Islander | | | 0 | | | 0 | | | 0 | | | 0 | |
White | | | 2 | | | 6 | | | 0 | | | 0 | |
Two or More Races or Ethnicities | | | 0 | | | 0 | | | 0 | | | 0 | |
LGBTQ+ | | | 0 | | |||||||||
Did Not Disclose Demographic Background | | | 0 | |
Name of Director | | | Age | | | Position | | | Class and Current Term | |
David Botstein, Ph.D. | | | | | Director | | | Class III, term expires | | |
William Ericson | | | | | Director | | | Class III, term expires | | |
Christian O. Henry | | | | | Director, President and Chief Executive Officer | | | Class I, term expires 2023 | | |
Randy Livingston | | | | | Director | | | Class II, term expires 2024 | | |
John F. Milligan, Ph.D. | | | | | Chair of the Board of Directors | | | Class I, term expires 2023 | | |
Marshall Mohr | | | | | Director | | | Class II, term expires 2024 | | |
Kathy Ordoñez | | | 72 | | | Director | | | Class III, term expires 2025 | |
Lucy Shapiro, Ph.D. | | | 82 | | | Director | | | Class I, term expires 2023 | |
Hannah A. Valantine, M.D. | | | 71 | | | Director | ||||
| | Class II, term expires 2024 | |
Name of Director | | Audit | | Compensation | | Corporate Governance and Nominating | | Science and Technology | | | Audit | | Compensation | | Corporate Governance and Nominating | | Science and Technology | | ||||||||
David Botstein, Ph.D. | | | | | | | | X | | | | | | | | | X | | ||||||||
William Ericson | | | | X (chair) | | X | | | | | | | X (chair) | | X | | | | ||||||||
Michael Hunkapiller, Ph.D. | | | | | | | | X(1) | | |||||||||||||||||
Randy Livingston | | X (chair) | | | | X | | | | | X (chair) | | | | X | | | | ||||||||
John F. Milligan, Ph.D. | | X | | X | | | | | | | X | | X | | | | | | ||||||||
Marshall Mohr | | X | | X | | | | | | | X | | X | | | | | | ||||||||
Kathy Ordoñez | | | | X(2) | | | | X (chair) | | | | | X(1) | | | | X (chair) | | ||||||||
Lucy Shapiro, Ph.D. | | | | | | X (chair) | | X | | | | | | | X (chair) | | X | | ||||||||
Hannah A. Valantine, M.D. | | | | | | X(3) | | X(3) | | | | | | | X | | X | | ||||||||
Number of meetings held during 2021 | | 6 | | 6 | | 4 | | 4 | | |||||||||||||||||
Number of meetings held during 2022 | | 5 | | 7 | | 3 | | 5 | |
Name | | Fees earned or paid in cash ($) | | Option Awards ($) | | All Other Compensation Reimbursement for Income Taxes ($) | | Total ($) | | | Fees earned or paid in cash ($) | | Option Awards ($)(1)(2) | | Total ($) | | ||||||||||||||||||||||||||||
David Botstein, Ph.D. | | | | 42,917 | | | | | 199,993 | | | | | — | | | | | 242,910 | | | |||||||||||||||||||||||
David Botstein, Ph.D | | | | 45,000 | | | | | 199,998 | | | | | 244,998 | | | ||||||||||||||||||||||||||||
William Ericson | | | | 56,917 | | | | | 199,993 | | | | | — | | | | | 256,910 | | | | | | 59,000 | | | | | 199,998 | | | | | 258,998 | | | |||||||
Michael Hunkapiller, Ph.D.(1) | | | | 14,583 | | | | | 199,993 | | | | | 21,838(2) | | | | | 236,414 | | | |||||||||||||||||||||||
Randy Livingston | | | | 62,917 | | | | | 199,993 | | | | | — | | | | | 262,910 | | | | | | 65,000 | | | | | 199,998 | | | | | 264,998 | | | |||||||
John F. Milligan, Ph.D. | | | | 92,834 | | | | | 199,993 | | | | | — | | | | | 292,827 | | | | | | 97,000 | | | | | 199,998 | | | | | 296,998 | | | |||||||
Marshall Mohr | | | | 54,917 | | | | | 199,993 | | | | | — | | | | | 254,910 | | | | | | 57,000 | | | | | 199,998 | | | | | 256,998 | | | |||||||
Kathy Ordoñez | | | | 49,083 | | | | | 199,993 | | | | | — | | | | | 249,076 | | | | | | 52,917 | | | | | 199,998 | | | | | 252,915 | | | |||||||
Lucy Shapiro, Ph.D. | | | | 52,917 | | | | | 199,993 | | | | | — | | | | | 252,910 | | | | | | 55,000 | | | | | 199,998 | | | | | 254,998 | | | |||||||
Hannah A. Valantine, M.D.(3) | | | | 29,167 | | | | | 449,996 | | | | | — | | | | | 479,163 | | | |||||||||||||||||||||||
Hannah A. Valantine, M.D. | | | | 50,000 | | | | | 199,998 | | | | | 249,998 | | |
Name | | | Aggregate Number of Stock Options Outstanding | | | Aggregate Number of Stock Options Exercisable | | | Aggregate Number of RSUs Outstanding | | |||||||||
David Botstein, Ph.D. | | | | | 84,384 | | | | | | 77,941 | | | | | | — | | |
William Ericson | | | | | 209,384 | | | | | | 202,941 | | | | | | — | | |
Michael Hunkapiller, Ph.D.(1) | | | | | 37,887 | | | | | | 27,275 | | | | | | 162,500 | | |
Randy Livingston | | | | | 184,384 | | | | | | 177,941 | | | | | | — | | |
John F. Milligan, Ph.D. | | | | | 144,384 | | | | | | 116,552 | | | | | | — | | |
Marshall Mohr | | | | | 269,384 | | | | | | 262,941 | | | | | | — | | |
Kathy Ordoñez(2) | | | | | 421,005 | | | | | | 410,914 | | | | | | 10,938 | | |
Lucy Shapiro, Ph.D. | | | | | 142,718 | | | | | | 136,275 | | | | | | — | | |
Hannah A. Valantine, M.D. | | | | | 28,992 | | | | | | — | | | | | | — | | |
Name | | | Aggregate Number of Stock Options Outstanding | | | Aggregate Number of Stock Options Exercisable | | ||||||
David Botstein, Ph.D. | | | | | 147,399 | | | | | | 121,143 | | |
William Ericson | | | | | 272,399 | | | | | | 246,143 | | |
Randy Livingston | | | | | 247,399 | | | | | | 221,143 | | |
John F. Milligan, Ph.D. | | | | | 207,399 | | | | | | 171,420 | | |
Marshall Mohr | | | | | 272,399 | | | | | | 246,143 | | |
Kathy Ordoñez(3) | | | | | 484,020 | | | | | | 457,764 | | |
Lucy Shapiro, Ph.D. | | | | | 205,733 | | | | | | 179,477 | | |
Hannah A. Valantine, M.D. | | | | | 92,007 | | | | | | 51,255 | | |
Name of Director | | Age | | Principal Occupation | | Director Since | | | Age | | Principal Occupation | | Director Since | | ||||||
Class III Nominees (term for which nominated expires in 2025) | | |||||||||||||||||||
Class I Nominees (term for which nominated expires in 2026) | Class I Nominees (term for which nominated expires in 2026) | | ||||||||||||||||||
Christian O. Henry | | 55 | | President and Chief Executive Officer of Pacific Biosciences of California, Inc. | | 2018 | | |||||||||||||
John F. Milligan, Ph.D. | | 62 | | Chair of the Board of Directors of Pacific Biosciences of California, Inc. | | 2013 | | |||||||||||||
Lucy Shapiro, Ph.D. | | 82 | | Virginia and D.K. Ludwig Professor of Cancer Research and the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University’s School of Medicine | | 2012 | | |||||||||||||
Class II Directors (term expires in 2024) | Class II Directors (term expires in 2024) | | ||||||||||||||||||
Randy Livingston | | 69 | | Vice President for Business Affairs and Chief Financial Officer of Stanford University | | 2009 | | |||||||||||||
Marshall Mohr | | 67 | | Executive Vice President, Global Business Services of Intuitive Surgical, Inc. | | 2012 | | |||||||||||||
Hannah A. Valantine, M.D. | | 71 | | Professor of Medicine (Cardiovascular) at the Stanford University Medical Center | | 2021 | | |||||||||||||
Class III Directors (term expires in 2025) | Class III Directors (term expires in 2025) | | ||||||||||||||||||
David Botstein, Ph.D. | | 79 | | Chief Scientific Officer of Calico Life Sciences | | 2012 | | | 80 | | Former Chief Scientific Officer of Calico Life Sciences | | 2012 | | ||||||
William Ericson | | 63 | | Founding Partner of Wildcat Venture Partners | | 2004 | | | 64 | | Founding Partner of Wildcat Venture Partners | | 2004 | | ||||||
Kathy Ordoñez | | 71 | | Director | | 2014 | | | 72 | | Director | | 2014 | | ||||||
Class I Directors (term expires in 2023) | | |||||||||||||||||||
Christian O. Henry | | 54 | | Chief Executive Officer and President of Pacific Biosciences of California, Inc. | | 2018 | | |||||||||||||
John F. Milligan, Ph.D. | | 61 | | Chair of the Board of Directors of Pacific Biosciences of California, Inc. | | 2013 | | |||||||||||||
Lucy Shapiro, Ph.D. | | 81 | | Virginia and D.K. Ludwig Professor of Cancer Research and the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University’s School of Medicine | | 2012 | | |||||||||||||
Class II Nominees (term expires in 2024) | | |||||||||||||||||||
Randy Livingston | | 68 | | Vice President for Business Affairs and Chief Financial Officer of Stanford University | | 2009 | | |||||||||||||
Marshall Mohr | | 66 | | Executive Vice President, Global Business Services of Intuitive Surgical, Inc. | | 2012 | | |||||||||||||
Hannah A. Valantine, M.D. | | 70 | | Professor of Medicine (Cardiovascular) at the Stanford University Medical Center | | 2021 | |
Fee Category | | 2021 | | 2020 | | | 2022 | | 2021 | | ||||||||||||||||
Audit Fees | | | $ | 2,035 | | | | $ | 1,255 | | | | | $ | 1,672 | | | | $ | 2,035 | | | ||||
Audit-related Fees | | | | 260 | | | | | — | | | | | | — | | | | | 260 | | | ||||
Tax Fees | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
All Other Fees | | | | 4 | | | | | — | | | | | | 2 | | | | | 4 | | | ||||
Total Fees | | | $ | 2,299 | | | | $ | 1,255 | | | | | $ | 1,674 | | | | $ | 2,299 | | |
Equity Plan(1) | | | Number of Shares Subject to Outstanding Options (#) | | | Weighted Average Exercise Price of Outstanding Options ($) | | | Weighted Average Remaining Term of Outstanding Options (Years) | | | Number of Shares Subject to Outstanding Restricted Stock Units (#) | | ||||||||||||
2020 Plan | | | | | 5,943,499 | | | | | | 11.56 | | | | | | 9.3 | | | | | | 5,271,095 | | |
2010 Plan(2) | | | | | 6,111,123 | | | | | | 5.09 | | | | | | 4.2 | | | | | | 1,559,025 | | |
Director Plan(2) | | | | | 688,334 | | | | | | 4.64 | | | | | | 4.2 | | | | | | — | | |
Omniome Plan | | | | | 861,358 | | | | | | 6.83 | | | | | | 9.0 | | | | | | 1,110,386 | | |
Inducement Plan | | | | | 2,246,874 | | | | | | 30.48 | | | | | | 8.8 | | | | | | 935,750 | | |
All Equity Plans | | | | | 15,851,188 | | | | | | 11.19 | | | | | | 7.0 | | | | | | 8,876,256 | | |
Name of Individual and Positions, or Group | | | Grant Date Fair Value of Stock Options ($) | | | Number of Shares Subject to Stock Options (#) | | | Aggregate Grant Date Fair Value of Restricted Stock Units ($) | | | Number of Shares Subject to Restricted Stock Units (#) | | ||||||||||||
Christian O. Henry, Chief Executive Officer and President | | | | | 752,502 | | | | | | 30,000 | | | | | | 695,550 | | | | | | 15,000 | | |
Susan G. Kim, Chief Financial Officer | | | | | 316,051 | | | | | | 12,600 | | | | | | 292,131 | | | | | | 6,300 | | |
Mark Van Oene, Chief Operating Officer(1) | | | | | 14,889,375 | | | | | | 750,000 | | | | | | 12,294,500 | | | | | | 335,000 | | |
Peter Fromen, Chief Commercial Officer(1) | | | | | 6,352,800 | | | | | | 320,000 | | | | | | 5,872,000 | | | | | | 160,000 | | |
Denis Zaccarin, Ph.D., Senior Vice President, Product Development | | | | | 504,176 | | | | | | 20,100 | | | | | | 466,019 | | | | | | 10,050 | | |
All current executive officers, as a group (4 people)(1) | | | | | 22,310,728 | | | | | | 1,112,600 | | | | | | 19,154,181 | | | | | | 516,300 | | |
All current directors, who are not executive officers, as a group (8 people)(2) | | | | | 1,849,949 | | | | | | 119,187 | | | | | | — | | | | | | — | | |
All employees, including all current officers who are not executive officers, as a group(3) | | | | | 36,611,527 | | | | | | 1,887,085 | | | | | | 112,687,102 | | | | | | 3,207,209 | | |
Name and address of beneficial owner (1) | | Number of Shares Owned(2) | | Right to Acquire Shares(3) | | Total Beneficial Ownership | | Percent of Class(4) | | | Number of Shares Owned(2) | | Right to Acquire Shares(3) | | Total Beneficial Ownership | | Percent of Class | | ||||||||||||||||||||||||||||||||
5% Stockholders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
ARK Investment Management, LLC(5) | | | | 26,383,103 | | | | | — | | | | | 26,383,103 | | | | | 11.8% | | | |||||||||||||||||||||||||||||
Jackson Square Partners, LLC(6) | | | | 22,423,915 | | | | | — | | | | | 22,423,915 | | | | | 10.0% | | | |||||||||||||||||||||||||||||
SB Northstar LP(7) | | | | 1,886,107 | | | | | 20,689,650 | | | | | 22,575,757 | | | | | 9.2% | | | |||||||||||||||||||||||||||||
The Vanguard Group(8) | | | | 19,854,876 | | | | | — | | | | | 19,854,876 | | | | | 8.9% | | | |||||||||||||||||||||||||||||
BlackRock Inc.(9) | | | | 16,569,244 | | | | | — | | | | | 16,569,244 | | | | | 7.4% | | | |||||||||||||||||||||||||||||
Capital International Investors(10) | | | | 12,106,318 | | | | | — | | | | | 12,106,318 | | | | | 5.4% | | | |||||||||||||||||||||||||||||
Nikko Asset Management Americas, Inc.(11) | | | | 11,915,025 | | | | | — | | | | | 11,915,025 | | | | | 5.3% | | | |||||||||||||||||||||||||||||
ARK Investment Management LLC(4) | | | | 25,691,681 | | | | | — | | | | | 25,691,681 | | | | | 10.3% | | | |||||||||||||||||||||||||||||
The Vanguard Group(5) | | | | 20,279,035 | | | | | — | | | | | 20,279,035 | | | | | 8.1% | | | |||||||||||||||||||||||||||||
BlackRock, Inc.(6) | | | | 18,534,459 | | | | | — | | | | | 18,534,459 | | | | | 7.4% | | | |||||||||||||||||||||||||||||
Madrone Opportunity Fund, L.P.(7) | | | | 16,415,933 | | | | | — | | | | | 16,415,933 | | | | | 6.6% | | | |||||||||||||||||||||||||||||
Jackson Square Partners, LLC(8) | | | | 15,005,177 | | | | | — | | | | | 15,005,177 | | | | | 6.0% | | | |||||||||||||||||||||||||||||
Nikko Asset Management Americas, Inc.(9) | | | | 14,166,193 | | | | | — | | | | | 14,166,193 | | | | | 5.7% | | | |||||||||||||||||||||||||||||
Named executive officers, directors, and director nominees: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
Christian O. Henry | | | | 98,608 | | | | | 767,908 | | | | | 866,516 | | | | | * | | | | | | 165,127 | | | | | 1,334,078 | | | | | 1,499,205 | | | | | * | | | ||||||||
David Botstein, Ph.D. | | | | — | | | | | 83,310 | | | | | 83,310 | | | | | * | | | | | | — | | | | | 147,399 | | | | | 147,399 | | | | | * | | | ||||||||
William Ericson | | | | 1,336 | | | | | 208,310 | | | | | 209,646 | | | | | * | | | | | | 18,795 | | | | | 247,399 | | | | | 266,194 | | | | | * | | | ||||||||
Randy Livingston | | | | — | | | | | 183,310 | | | | | 183,310 | | | | | * | | | | | | — | | | | | 247,399 | | | | | 247,399 | | | | | * | | | ||||||||
John F. Milligan, Ph.D. | | | | 110,000 | | | | | 126,782 | | | | | 236,782 | | | | | * | | | | | | 110,000 | | | | | 202,538 | | | | | 312,538 | | | | | * | | | ||||||||
Marshall Mohr | | | | 25,000 | | | | | 243,310 | | | | | 268,310 | | | | | * | | | | | | 60,000 | | | | | 272,399 | | | | | 332,399 | | | | | * | | | ||||||||
Kathy Ordoñez | | | | 36,093 | | | | | 419,931 | | | | | 456,024 | | | | | * | | | | | | 18,595 | | | | | 484,020 | | | | | 502,615 | | | | | * | | | ||||||||
Lucy Shapiro, Ph.D. | | | | — | | | | | 141,644 | | | | | 141,644 | | | | | * | | | | | | — | | | | | 205,733 | | | | | 205,733 | | | | | * | | | ||||||||
Hannah A. Valantine, M.D. | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | 81,537 | | | | | 81,537 | | | | | * | | | ||||||||
Peter Fromen | | | | 20,280 | | | | | 119,111 | | | | | 139,391 | | | | | * | | | |||||||||||||||||||||||||||||
Jeff Eidel(10) | | | | 6,610 | | | | | — | | | | | 6,610 | | | | | * | | | |||||||||||||||||||||||||||||
Susan G. Kim | | | | 19,229 | | | | | 172,227 | | | | | 191,456 | | | | | * | | | | | | 51,155 | | | | | 348,437 | | | | | 399,592 | | | | | * | | | ||||||||
Mark Van Oene | | | | 43,778 | | | | | 268,048 | | | | | 311,826 | | | | | * | | | | | | 115,496 | | | | | 572,868 | | | | | 688,364 | | | | | * | | | ||||||||
Denis Zaccarin, Ph.D. | | | | 59,279 | | | | | 232,505 | | | | | 291,784 | | | | | * | | | |||||||||||||||||||||||||||||
All current directors and executive officers as a group (12 people)(12 ) | | | | 354,324 | | | | | 2,733,891 | | | | | 3,088,215 | | | | | 1.4% | | | |||||||||||||||||||||||||||||
All current directors and executive officers as a group (12 people) | | | | 545,778 | | | | | 4,143,807 | | | | | 4,689,585 | | | | | 1.9% | | |
Name | | | Position | |
Christian O. Henry | | | President and Chief Executive Officer | |
Susan G. Kim | | | Chief Financial Officer | |
Mark Van Oene | | | Chief Operating Officer | |
| | Chief Commercial Officer | | |
| | |
Element | | | Performance Period | | | Objective | |
Base Salary | | | Annual | | | • Recognizes an individual’s contribution and performance • Rewards for the experience, education and criticality to the business • Serves as an important retention vehicle | |
Short-term Cash Incentives | | | Annual | | | • Rewards achievement of financial and non-financial goals directly tied to the strategic priorities • In | |
Annual Equity Awards (stock options and RSUs) | | | Long-term | | | • Supports the achievement of strong stock price growth • Aligns the interests of executives and stockholders over time | |
Element | | | Performance Period | | | Objective | |
| | | | | | • Serves as an important retention tool with awards vesting over time tied to continued service • Options may vest over one to four years, with a ten-year term • RSUs vest in equal installments over two to four years, on each anniversary of the grant date | |
What We Do | | | What We | | | ||||||||
Pay for performance philosophy and culture | | | Excise tax gross-ups | | | ||||||||
Majority of pay is variable and linked to corporate and individual performance | | | Significant perquisites | | | ||||||||
Double-trigger change-in-control equity provisions | | | Guaranteed salary increases | | | ||||||||
Compensation recoupment (“clawback”) policy | | | Contracts that guarantee employment | | | ||||||||
Engage an independent compensation consultant | | | |||||||||||
Margin accounts, hedging, pledging, derivatives or short sale transactions in | | ||||||||||||
| | ||||||||||||
Responsible use of shares in our long-term incentive program | | | Repricing stock options without stockholder approval | | |||||||||
| | ||||||||||||
Annually assesses compensation risk | | | | | | | |
| 10x Genomics, | |||||||
| | Guardant Health, Inc. | | | | |||
| | | Invitae Corporation | | | | ||
| | | iRhythm Technologies, Inc. | | | Quanterix Corporation | | |
| | | | | Repligen Corporation | | ||
| CareDx, Inc. | | | NanoString Technologies, Inc. | | | Twist Bioscience Corporation | |
| | | | | Veracyte, Inc. | | ||
| | | | | | |
Name | | As of Fiscal Year End 2020 ($) | | As of Fiscal Year End 2021 ($) | | Change (%) | | | As of Fiscal Year End 2021 ($) | | As of Fiscal Year End 2022 ($) | | Change (%) | | ||||||||||||||||||||||||
Christian O. Henry | | | | 650,000 | | | | | 650,000 | | | | | 0% | | | | | | 650,000 | | | | | 670,000 | | | | | 3.1% | | | ||||||
Susan G. Kim | | | | 415,000 | | | | | 430,000 | | | | | 3.6% | | | | | | 430,000 | | | | | 443,000 | | | | | 3.0% | | | ||||||
Mark Van Oene | | | | — | | | | | 550,000 | | | | | — | | | | | | 550,000 | | | | | 567,000 | | | | | 3.1% | | | ||||||
Jeff Eidel(1) | | | | — | | | | | 438,000 | | | | | — | | | ||||||||||||||||||||||
Peter Fromen(2) | | | | — | | | | | 425,000 | | | | | — | | | | | | 425,000 | | | | | 438,000 | | | | | 3.1% | | | ||||||
Denis Zaccarin | | | | 330,000 | | | | | 345,000 | | | | | 4.5% | | |
Name | | Target Incentive Opportunity for 2021 as Percentage of Base Salary | | Target Incentive Opportunity for 2021 ($) | | | Target Incentive Opportunity for 2022 as Percentage of Base Salary(1) | | Target Incentive Opportunity for 2022 ($) | | ||||||||||||||||
Christian O. Henry | | | | 100% | | | | | 650,000 | | | | | | 100% | | | | | 670,000 | | | ||||
Susan G. Kim | | | | 50% | | | | | 215,000 | | | | | | 50% | | | | | 221,500 | | | ||||
Mark Van Oene | | | | 60% | | | | | 330,000 | | | | | | 60% | | | | | 340,200 | | | ||||
Jeff Eidel(1) | | | | 50% | | | | | 82,800 | | | |||||||||||||||
Peter Fromen | | | | 50% | | | | | 212,500 | | | | | | 50% | | | | | 219,000 | | | ||||
Denis Zaccarin | | | | 45% | | | | | 155,250 | | |
Performance Objectives | | | Achievement | | |
Financial Goals (Collectively Weighted at 20%) | | | | ||
Exceeding $180 million in fiscal year 2022 revenue | | | $128.3 million, resulting in achievement at | | |
Exceeding non-GAAP gross margin of 47% in fiscal year 2022 | | | 39%, resulting in achievement at 0% | | |
Achieving Adjusted EBITDA of $(190 million) in fiscal year 2022 | | | $(216 million), resulting in achievement at 0% | | |
Non-Financial Goals (Collectively Weighted at 80%) | | | | | |
| | | |||
| | | |||
| | ||||
3 goals achieved at total | | ||||
Developing an inspired workforce, and optimizing organizational structure, including the integration of Omniome into the organization (collectively weighted at | |||||
10%) Total Score | |||||
| | ||||
4 goals achieved at a total | approximately 6.3% achievement | ||||
Of the 25 goals, including both financial and non-financial goals, achievement at a total of | |
Name | | 2021 Target Bonus Opportunity (as a % of salary) | | 2021 Salary | | 2021 Actual Bonus (as a % of Target Bonus Opportunity) | | 2021 Actual Bonus ($) | | | 2021 Target Bonus Opportunity (as a % of salary) | | 2022 Salary | | 2022 Actual Bonus (as a% of Target Bonus Opportunity) | | 2022 Actual Bonus ($) | | ||||||||||||||||||||||||||||||||
Christian O. Henry | | | | 100% | | | | $ | 650,000 | | | | | 116.1% | | | | $ | 754,650 | | | | | | 100% | | | | $ | 670,000 | | | | | 56% | | | | $ | 375,200 | | | ||||||||
Susan G. Kim | | | | 50% | | | | $ | 430,000 | | | | | 116.1% | | | | $ | 249,615 | | | | | | 50% | | | | $ | 443,000 | | | | | 56% | | | | $ | 124,040 | | | ||||||||
Mark Van Oene | | | | 60% | | | | $ | 550,000 | | | | | 116.1% | | | | $ | 375,782(1) | | | | | | 60% | | | | $ | 567,000 | | | | | 56% | | | | $ | 190,512 | | | ||||||||
Jeff Eidel | | | | 50% | | | | $ | 438,000 | | | | | 56% | | | | $ | 46,368(1) | | | |||||||||||||||||||||||||||||
Peter Fromen | | | | 50% | | | | $ | 425,000 | | | | | 116.1% | | | | $ | 241,981(1) | | | | | | 50% | | | | $ | 438,000 | | | | | — | | | | | —(2) | | | ||||||||
Denis Zaccarin | | | | 45% | | | | $ | 345,000 | | | | | 116.1% | | | | $ | 180,245 | | |
| | New Hire Equity Grants(2) | | | Annual Equity Grants(1) | | New Hire Equity Grants(1) | | ||||||||||||||||||||||||||||||||||||||||||
Name | | RSUs (#) | | Stock Options (#) | | RSUs (#) | | Stock Options (#) | | | RSUs (#) | | Stock Options (#) | | RSUs (#) | | Stock Options (#) | | ||||||||||||||||||||||||||||||||
Christian O. Henry | | | | 15,000 | | | | | 30,000 | | | | | — | | | | | — | | | | | | 107,500 | | | | | 642,300 | | | | | — | | | | | — | | | ||||||||
Susan G. Kim | | | | 6,300 | | | | | 12,600 | | | | | — | | | | | — | | | | | | 40,000 | | | | | 239,000 | | | | | — | | | | | — | | | ||||||||
Mark Van Oene | | | | — | | | | | — | | | | | 335,000 | | | | | 750,000 | | | | | | 372,500 | | | | | 433,200 | | | | | — | | | | | — | | | ||||||||
Peter Fromen(4) | | | | — | | | | | — | | | | | 160,000 | | | | | 320,000 | | | |||||||||||||||||||||||||||||
Denis Zaccarin | | | | 10,050 | | | | | 20,100 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||
Jeff Eidel(3) | | | | — | | | | | — | | | | | 300,000 | | | | | 600,000(4) | | | |||||||||||||||||||||||||||||
Peter Fromen | | | | 50,000 | | | | | 298,700 | | | | | — | | | | | — | | |
Name and principal position | | | Year | | | Salary ($) | | | Bonus ($) | | | Stock Awards ($)(1) | | | Option Awards ($)(2) | | | Non-equity Incentive Plan Compensation ($)(3) | | | All Other Compensation ($) | | | Total ($) | | ||||||||||||||||||||||||
Christian O. Henry(4) President, Chief Executive Officer | | | | | 2021 | | | | | | 650,000 | | | | | | — | | | | | | 695,550 | | | | | | 752,502 | | | | | | 754,650 | | | | | | 14,229(5) | | | | | | 2,866,931 | | |
| | | 2020(6) | | | | | | 194,583 | | | | | | 31,677 | | | | | | 5,490,000 | | | | | | 6,345,900 | | | | | | 183,323 | | | | | | 233,287 | | | | | | 12,478,770 | | | ||
Susan G. Kim(7) Chief Financial Officer | | | | | 2021 | | | | | | 421,875 | | | | | | — | | | | | | 292,131 | | | | | | 316,051 | | | | | | 249,615 | | | | | | — | | | | | | 1,279,672 | | |
| | | 2020 | | | | | | 108,538 | | | | | | 95,224(8) | | | | | | 1,440,000 | | | | | | 2,219,320 | | | | | | 35,109 | | | | | | — | | | | | | 3,898,191 | | | ||
Mark Van Oene(9) Chief Operating Officer | | | | | 2021 | | | | | | 539,776 | | | | | | 200,000(10) | | | | | | 12,294,500 | | | | | | 14,889,375 | | | | | | 375,782 | | | | | | — | | | | | | 28,299,433 | | |
Peter Fromen(11) Chief Commercial Officer | | | | | 2021 | | | | | | 417,099 | | | | | | 125,000(10) | | | | | | 5,872,000 | | | | | | 6,352,800 | | | | | | 241,981 | | | | | | 329,010(12) | | | | | | 13,337,890 | | |
Denis Zaccarin, Ph.D. Senior Vice President, Product Development | | | | | 2021 | | | | | | 330,529 | | | | | | — | | | | | | 466,019 | | | | | | 504,176 | | | | | | 180,245 | | | | | | — | | | | | | 1,480,969 | | |
| | | 2020 | | | | | | 321,625 | | | | | | 43,421(13) | | | | | | 270,600 | | | | | | — | | | | | | 75,379 | | | | | | — | | | | | | 711,025 | | |
Name and principal position | | | Year | | | Salary ($) | | | Bonus ($) | | | Stock Awards ($)(1) | | | Option Awards ($)(1) | | | Non-equity Incentive Plan Compensation ($)(2) | | | All Other Compensation ($) | | | Total ($) | | |||||||||||||||||||||
Christian O. Henry(3) President, Chief Executive Officer | | | 2022 | | | | | 666,667 | | | | | | — | | | | | | 1,257,750 | | | | | | 4,260,247 | | | | | | 375,200 | | | | | | 56,387(4) | | | | | | 6,616,251 | | |
| 2021 | | | | | 650,000 | | | | | | — | | | | | | 695,550 | | | | | | 752,502 | | | | | | 754,650 | | | | | | 14,229(5) | | | | | | 2,866,931 | | | ||
| 2020 | | | | | 194,583 | | | | | | 31,677(6) | | | | | | 5,490,000 | | | | | | 6,345,900 | | | | | | 183,323 | | | | | | 233,287(7) | | | | | | 12,478,770 | | | ||
Susan G. Kim(8) Chief Financial Officer | | | 2022 | | | | | 440,833 | | | | | | — | | | | | | 468,000 | | | | | | 1,585,239 | | | | | | 124,040 | | | | | | — | | | | | | 2,618,112 | | |
| 2021 | | | | | 421,875 | | | | | | — | | | | | | 292,131 | | | | | | 316,051 | | | | | | 249,615 | | | | | | — | | | | | | 1,279,672 | | | ||
| 2020 | | | | | 108,538 | | | | | | 95,224(9) | | | | | | 1,440,000 | | | | | | 2,219,320 | | | | | | 35,109 | | | | | | — | | | | | | 3,898,191 | | | ||
Mark Van Oene(10) Chief Operating Officer | | | 2022 | | | | | 564,167 | | | | | | — | | | | | | 2,918,250 | | | | | | 2,873,329 | | | | | | 190,512 | | | | | | 17,433(11) | | | | | | 6,563,691 | | |
| 2021 | | | | | 539,776 | | | | | | 200,000(12) | | | | | | 12,294,500 | | | | | | 14,889,375 | | | | | | 375,782 | | | | | | — | | | | | | 28,299,433 | | | ||
Jeff Eidel(13) Chief Commercial Officer | | | 2022 | | | | | 164,250 | | | | | | 225,000(12) | | | | | | 2,400,000 | | | | | | 2,965,867 | | | | | | 46,368 | | | | | | — | | | | | | 5,801,485 | | |
Peter Fromen(14) Former Chief Commercial Officer | | | 2022 | | | | | 170,506 | | | | | | — | | | | | | 585,000 | | | | | | 1,981,217 | | | | | | — | | | | | | 168,976(15) | | | | | | 2,905,699 | | |
| 2021 | | | | | 417,099 | | | | | | 125,000(12) | | | | | | 5,872,000 | | | | | | 6,352,800 | | | | | | 241,981 | | | | | | 329,010(16) | | | | | | 13,337,890 | | |
| | | | | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards ($)(1) | | Estimated Future Payments Under Equity Incentive Plan Awards (#) | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Grant Date | | Threshold | | Target | | Maximum | | Threshold | | Target | | Maximum | | Other Stock Awards: Number of Shares of Stock or Units (#) | | Other Option Awards: Number of Securities Underlying Options (#) | | Exercise or Base Price of Option Awards ($/Sh) | | Grant Date Fair Value of Stock and Option Awards ($)(2) | | | Grant Date | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards ($)(1) | | Estimated Future Payments Under Equity Incentive Plan Awards (#) | | | Other Stock Awards: Number of Shares of Stock or Units (#) | | Other Option Awards: Number of Securities Underlying Options (#) | | Exercise or Base Price of Option Awards ($/Sh) | | Grant Date Fair Value of Stock and Option Awards ($)(2) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Christian O. Henry........ | | | | | 02/03/2021(3) | | | | | 195,000 | | | | | 650,000 | | | | | 1,137,500 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/16/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 15,000(4) | | | | | — | | | | | — | | | | | 695,550 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/16/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 30,000(4) | | | | | 46.37 | | | | | 752,502 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Susan G. Kim................ | | | | | 02/03/2021(3) | | | | | 64,500 | | | | | 215,000 | | | | | 376,250 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/16/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 6,300(4) | | | | | — | | | | | — | | | | | 292,131 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/16/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 12,600(4) | | | | | 46.37 | | | | | 316,051 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mark Van Oene............. | | | | | 01/08/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 335,000(5) | | | | | — | | | | | — | | | | | 12,294,500 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/08/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 750,000(5) | | | | | 36.70 | | | | | 14,889,375 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/03/2021(3) | | | | | 99,000 | | | | | 330,000 | | | | | 577,500 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Peter Fromen................. | | | | | 01/08/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 160,000(5) | | | | | — | | | | | — | | | | | 5,872,000 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/08/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 320,000(5) | | | | | 36.70 | | | | | 6,352,800 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/03/2021(3) | | | | | 63,750 | | | | | 212,500 | | | | | 371,875 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Denis Zaccarin, Ph.D..... | | | | | 02/03/2021(3) | | | | | 46,575 | | | | | 155,250 | | | | | 271,688 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/16/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 10,050(4) | | | | | — | | | | | — | | | | | 466,019 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/16/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 20,100(4) | | | | | 46.37 | | | | | 504,176 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Grant Date | | | Threshold | | Target | | Maximum | | Threshold | | Target | | Maximum | | | Other Stock Awards: Number of Shares of Stock or Units (#) | | Other Option Awards: Number of Securities Underlying Options (#) | | Exercise or Base Price of Option Awards ($/Sh) | | Grant Date Fair Value of Stock and Option Awards ($)(2) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | — | | | | | 670,000 | | | | | 804,000 | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Christian O. Henry | | | | | 03/02/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 107,500(4) | | | | | — | | | | | — | | | | | 1,257,750 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 03/02/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 642,300(4) | | | | | 11.70 | | | | | 4,260,247 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/2022(3) | | | | | — | | | | | 221,500 | | | | | 265,800 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Susan G. Kim | | | | | 03/02/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 40,000(4) | | | | | — | | | | | — | | | | | 468,000 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 03/02/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 239,000(4) | | | | | 11.70 | | | | | 1,585,239 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/2022(3) | | | | | — | | | | | 340,200 | | | | | 408,240 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mark Van Oene | | | | | 03/02/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 72,500(4) | | | | | — | | | | | — | | | | | 848,250 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 03/02/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 433,200(4) | | | | | 11.70 | | | | | 2,873,329 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 08/25/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 300,000(4) | | | | | — | | | | | — | | | | | 2,070,000 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/2022(3) | | | | | — | | | | | 82,800(5) | | | | | 99,360(5) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jeff Eidel | | | | | 08/16/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 300,000(4) | | | | | — | | | | | — | | | | | 2,400,000 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 08/16/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 475,000(6) | | | | | 8.00 | | | | | 2,347,978 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 08/16/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 125,000(4) | | | | | 8.00 | | | | | 617,889 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/2022(3) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Peter Fromen | | | | | 03/02/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 50,000(4) | | | | | — | | | | | — | | | | | 585,000 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 03/02/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 298,700(4) | | | | | 11.70 | | | | | 1,981,217 | | |
| | | | | | | | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Options | | | Option Exercise Price ($/sh) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(1) | | | Market Value of Shares or Units of Stock That Have Not Vested ($)(2) | | ||||||||||||||||||||||||
| Exercisable (#) | | | Unexercisable (#) | | ||||||||||||||||||||||||||||||||||||||
Christian O. Henry | | | | | 7/27/2018 | | | | | | 35,000 | | | | | | — | | | | | | 3.66 | | | | | | 7/27/2028 | | | | | | | | | | | | | | |
| | | 3/16/2020 | | | | | | 32,083 | | | | | | 2,917(3) | | | | | | 2.45 | | | | | | 3/16/2030 | | | | | | | | | | | | | | | ||
| | | 8/4/2020 | | | | | | 46,499 | | | | | | — | | | | | | 3.89 | | | | | | 8/4/2030 | | | | | | | | | | | | | | | ||
| | | 9/15/2020 | | | | | | 843,742 | | | | | | 656,258(4) | | | | | | 7.32 | | | | | | 9/15/2030 | | | | | | | | | | | | | | | ||
| | | 9/15/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 375,000(5) | | | | | | 3,067,500 | | | ||
| | | 2/16/2021 | | | | | | 13,749 | | | | | | 16,251(6) | | | | | | 46.37 | | | | | | 2/16/2031 | | | | | | | | | | | | | | | ||
| | | 2/16/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,250(5) | | | | | | 92,025 | | | ||
| | | 3/2/2022 | | | | | | 120,429 | | | | | | 521,871(6) | | | | | | 11.70 | | | | | | 3/2/2032 | | | | | | | | | | | | | | | ||
| | | 3/2/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 107,500(5) | | | | | | 879,350 | | | ||
Susan G. Kim | | | | | 9/28/2020 | | | | | | 224,998 | | | | | | 175,002(4) | | | | | | 9.60 | | | | | | 9/28/2030 | | | | | | | | | | | | | | |
| | | 9/28/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 75,000(5) | | | | | | 613,500 | | | ||
| | | 2/16/2021 | | | | | | 5,774 | | | | | | 6,826(6) | | | | | | 46.37 | | | | | | 2/16/2031 | | | | | | | | | | | | | | | ||
| | | 2/16/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,725(5) | | | | | | 38,651 | | | ||
| | | 3/2/2022 | | | | | | 44,811 | | | | | | 194,189(6) | | | | | | 11.70 | | | | | | 3/2/2032 | | | | | | | | | | | | | | | ||
| | | 3/2/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 40,000(5) | | | | | | 327,200 | | | ||
Mark Van Oene | | | | | 1/8/2021 | | | | | | 359,372 | | | | | | 390,628(4) | | | | | | 36.70 | | | | | | 1/8/2031 | | | | | | | | | | | | | | |
| | | 1/8/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 251,250(5) | | | | | | 2,055,225 | | | ||
| | | 3/2/2022 | | | | | | 81,223 | | | | | | 351,977(6) | | | | | | 11.70 | | | | | | 3/2/2032 | | | | | | | | | | | | | | | ||
| | | 3/2/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 72,500(5) | | | | | | 593,050 | | | ||
| | | 8/25/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 300,000(5) | | | | | | 2,454,000 | | |
| | | | | | | | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||
| | | | | | | | | Number of Securities Underlying Unexercised Options | | | Option Exercise Price ($/sh) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(1) | | | Market Value of Shares or Units of Stock That Have Not Vested ($)(2) | | |||||||||||||||||||||
Name | | | Grant Date | | | Exercisable (#) | | | Unexercisable (#) | | |||||||||||||||||||||||||||||||||
Christian O. Henry................................ | | | | | 7/27/2018 | | | | | | 35,000 | | | | | | — | | | | | | 3.66 | | | | | | 7/27/2028 | | | | | | | | | | | | | | |
| | | 3/16/2020 | | | | | | 20,416 | | | | | | 14,584(3) | | | | | | 2.45 | | | | | | 3/16/2030 | | | | | | | | | | | | | | | ||
| | | 8/4/2020 | | | | | | 46,499 | | | | | | — | | | | | | 3.89 | | | | | | 8/4/2030 | | | | | | | | | | | | | | | ||
| | | 9/15/2020 | | | | | | 468,748 | | | | | | 1,031,252(4) | | | | | | 7.32 | | | | | | 9/15/2030 | | | | | | | | | | | | | | | ||
| | | 9/15/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 562,500(5) | | | | | | 11,508,750 | | | ||
| | | 2/16/2021 | | | | | | 6,249 | | | | | | 23,751(6) | | | | | | 46.37 | | | | | | 2/16/2031 | | | | | | | | | | | | | | | ||
| | | 2/16/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,000(5) | | | | | | 306,900 | | | ||
Susan G. Kim........................................ | | | | | 9/28/2020 | | | | | | 124,999 | | | | | | 275,001(4) | | | | | | 9.60 | | | | | | 9/28/2030 | | | | | | | | | | | | | | |
| | | 9/28/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 112,500(5) | | | | | | 2,301,750 | | | ||
| | | 2/16/2021 | | | | | | 2,624 | | | | | | 9,976(6) | | | | | | 46.37 | | | | | | 2/16/2031 | | | | | | | | | | | | | | | ||
| | | 2/16/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 6,300(5) | | | | | | 128,898 | | | ||
Mark Van Oene..................................... | | | | | 1/8/2021 | | | | | | 750,000 | | | | | | — | | | | | | 36.70 | | | | | | 1/8/2031 | | | | | | | | | | | | | | |
| | | 1/8/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 335,000(5) | | | | | | 6,854,100 | | | ||
Peter Fromen......................................... | | | | | 1/8/2021 | | | | | | 320,000 | | | | | | — | | | | | | 36.70 | | | | | | 1/8/2031 | | | | | | | | | | | | | | |
| | | 1/8/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 160,000(5) | | | | | | 3,273,600 | | | ||
Denis Zaccarin, Ph.D............................. | | | | | 2/17/2015 | | | | | | 50,000 | | | | | | — | | | | | | 6.91 | | | | | | 2/17/2025 | | | | | | | | | | | | | | |
| | | 2/16/2016 | | | | | | 60,000 | | | | | | — | | | | | | 8.90 | | | | | | 2/16/2026 | | | | | | | | | | | | | | | ||
| | | 2/15/2017 | | | | | | 65,000 | | | | | | — | | | | | | 5.27 | | | | | | 2/15/2027 | | | | | | | | | | | | | | | ||
| | | 2/15/2018 | | | | | | 43,124 | | | | | | 1,876(6) | | | | | | 2.54 | | | | | | 2/15/2028 | | | | | | | | | | | | | | | ||
| | | 2/15/2018 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,500(5) | | | | | | 51,150 | | | ||
| | | 2/18/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 30,000(5) | | | | | | 613,800 | | | ||
| | | 2/18/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,000(7) | | | | | | 204,600 | | | ||
| | | 2/16/2021 | | | | | | 4,187 | | | | | | 15,913(6) | | | | | | 46.37 | | | | | | 2/16/2031 | | | | | | | | | | | | | | | ||
| | | 2/16/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,050(5) | | | | | | 205,623 | | |
| | | | | | | | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Options | | | Option Exercise Price ($/sh) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(1) | | | Market Value of Shares or Units of Stock That Have Not Vested ($)(2) | | ||||||||||||||||||||||||
| Exercisable (#) | | | Unexercisable (#) | | ||||||||||||||||||||||||||||||||||||||
Jeff Eidel | | | | | 8/16/2022 | | | | | | — | | | | | | 125,000(4) | | | | | | 8.00 | | | | | | 8/16/2032 | | | | | | | | | | | | | | |
| | | 8/16/2022 | | | | | | — | | | | | | 475,000(4) | | | | | | 8.00 | | | | | | 8/16/2032 | | | | | | | | | | | | | | | ||
| | | 8/16/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 300,000(5) | | | | | | 2,454,000 | | |
| | Option Awards | | Stock Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||
Name | | Number of Shares Acquired on Exercises (#) | | Value Realized on Exercise ($) | | Number of Shares Acquired on Vesting (#) | | Value Realized on Vesting ($) | | | Number of Shares Acquired on Vesting (#) | | Value Realized on Vesting ($) | | ||||||||||||||||||||||||
Christian O. Henry | | | | — | | | | | — | | | | | 187,500 | | | | | 5,182,500 | | | | | | 191,250 | | | | | 1,283,925 | | | ||||||
Susan G. Kim | | | | — | | | | | — | | | | | 37,500 | | | | | 932,625 | | | | | | 39,075 | | | | | 238,086 | | | ||||||
Mark Van Oene | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 83,750 | | | | | 1,403,650 | | | ||||||
Jeff Eidel | | | | — | | | | | — | | | |||||||||||||||||||||||||||
Peter Fromen | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 40,000 | | | | | 670,400 | | | ||||||
Denis Zaccarin, Ph.D. | | | | 103,000 | | | | | 4,337,040 | | | | | 22,500 | | | | | 835,200 | | |
Compensation and Benefits | | | Involuntary Termination ($) | | | Involuntary Termination On or Within 12 Months Following Change In Control ($) | | ||||||
Christian O. Henry Salary Performance-based cash bonus Equity acceleration(1) Health care benefits Total | | | | ||||||||||
| | | 975,000 | | | | | | 975,000 | | | ||
| | | — | | | | | | 650,000 | | | ||
| | | 200,831 | | | | | | 25,628,959 | | | ||
| | | 52,759 | | | | | | 52,759 | | | ||
| | | 1,228,590 | | | | | | 27,306,718 | | | ||
Susan G. Kim Salary Performance-based cash bonus Equity acceleration(1) Health care benefits Total | | | | ||||||||||
| | | 430,000 | | | | | | 430,000 | | | ||
| | | — | | | | | | 215,000 | | | ||
| | | — | | | | | | 5,417,159 | | | ||
| | | — | | | | | | — | | | ||
| | | 430,000 | | | | | | 6,062,159 | | | ||
Mark Van Oene Salary Performance-based cash bonus Equity acceleration(1) Health care benefits Total | | | | ||||||||||
| | | 550,000 | | | | | | 550,000 | | | ||
| | | — | | | | | | 330,000 | | | ||
| | | — | | | | | | 6,854,100 | | | ||
| | | 31,291 | | | | | | 31,291 | | | ||
| | | 581,291 | | | | | | 7,765,391 | | | ||
Peter Fromen Salary Performance-based cash bonus Equity acceleration(1) Health care benefits Total | | | | ||||||||||
| | | 425,000 | | | | | | 425,000 | | | ||
| | | — | | | | | | 212,500 | | | ||
| | | — | | | | | | 3,273,600 | | | ||
| | | 39,070 | | | | | | 39,070 | | | ||
| | | 464,070 | | | | | | 3,950,170 | | | ||
Denis Zaccarin, Ph.D. Salary Performance-based cash bonus Equity acceleration(1) Health care benefits Total | | | | ||||||||||
| | | 172,500 | | | | | | 258,750 | | | ||
| | | — | | | | | | 155,250 | | | ||
| | | — | | | | | | 1,108,791 | | | ||
| | | 11,313 | | | | | | 16,969 | | | ||
| | | 183,813 | | | | | | 1,539,760 | | |
Compensation and Benefits(1) | | | Involuntary Termination ($) | | | Involuntary Termination On or Within 12 Months Following Change In Control ($) | | ||||||
Christian O. Henry Salary Performance-based cash bonus Equity acceleration(2) Health care benefits Total | | | | | 1,005,000 — 428,474 46,332 1,479,806 | | | | | | 1,005,000 670,000 4,619,971 46,332 6,341,303 | | |
Susan G. Kim Salary Performance-based cash bonus Equity acceleration(2) Health care benefits Total | | | | | 443,000 — — — 443,000 | | | | | | 443,000 221,500 979,351 — 1,643,851 | | |
Compensation and Benefits(1) | | | Involuntary Termination ($) | | | Involuntary Termination On or Within 12 Months Following Change In Control ($) | | ||||||
Mark Van Oene Salary Performance-based cash bonus Equity acceleration(2) Health care benefits Total | | | | | 567,000 — — 30,888 597,888 | | | | | | 567,000 340,200 5,102,275 30,888 6,040,363 | | |
Jeff Eidel Salary Performance-based cash bonus Equity acceleration(2) Health care benefits Total | | | | | 438,000 — — 30,888 468,888 | | | | | | 438,000 219,000 2,562,000 30,888 3,249,888 | | |
Year | | | Reported Summary Compensation Table (“SCT”) Total for PEO 1 | | | Compensation Actually Paid to PEO 1(2) | | | Reported Summary Compensation Table Total for PEO 2 | | | Compensation Actually Paid to PEO 2(2) | | | Average Reported Summary Compensation Table Total for Non-PEO NEOs(3) | | | Average Compensation Actually Paid to Non-PEO NEOs(2)(3) | | | Value of Initial Fixed $100 Investment(1) | | | Net Income (in millions) | | | Company Selected Measure: Revenue (in millions)(5) | | |||||||||||||||||||||||||||||||||
| Company Total Shareholder Return | | | Peer Group Shareholder Return(4) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2022 | | | | $ | 6,616,251 | | | | | $ | (13,137,692) | | | | | | N/A | | | | | | N/A | | | | | $ | 4,472,247 | | | | | $ | (842,693) | | | | | $ | 159 | | | | | $ | 114 | | | | | $ | (314.2) | | | | | $ | 128.3 | | |
2021 | | | | $ | 2,866,931 | | | | | $ | (6,449,458) | | | | | | N/A | | | | | | N/A | | | | | $ | 11,099,491 | | | | | $ | 6,128,515 | | | | | $ | 398 | | | | | $ | 126 | | | | | $ | (181.2) | | | | | $ | 130.5 | | |
2020 | | | | $ | 12,478,770 | | | | | $ | 51,604,237 | | | | | $ | 1,717,050 | | | | | $ | 8,398,519 | | | | | $ | 1,855,694 | | | | | $ | 4,749,166 | | | | | $ | 505 | | | | | $ | 126 | | | | | $ | 29.4 | | | | | $ | 78.9 | | |
Year | | | Executives | | | SCT Total | | | Deduct SCT Stock & Option Awards | | | Add Year-End Value of Unvested Awards Granted in Year(a) | | | Add Change in Value of Unvested Awards Granted in Prior Years(a) | | | Add Fair Value of Vested Awards Granted in Year(a) | | | Add Change in Value of Vested Awards Granted in Prior Years(a) | | | Deduct Fair Value of Forfeited Awards in Year(a) | | |||||||||||||||||||||
2022 2022 | | | PEO 1 | | | | $ | 6,616,251 | | | | | $ | (5,517,997) | | | | | $ | 3,572,661 | | | | | $ | (11,593,565) | | | | | $ | 485,101 | | | | | $ | (6,700,144) | | | | | $ | 0 | | |
| Non-PEO NEOs* | | | | $ | 4,472,247 | | | | | $ | (3,944,226) | | | | | $ | 2,962,458 | | | | | $ | (2,161,553) | | | | | $ | 141,415 | | | | | $ | (1,075,233) | | | | | $ | (1,237,802) | | | ||
2021 2021 | | | PEO 1 | | | | $ | 2,866,931 | | | | | $ | (1,448,052) | | | | | $ | 574,247 | | | | | $ | (8,880,638) | | | | | $ | 94,868 | | | | | $ | 343,184 | | | | | $ | 0 | | |
| Non-PEO NEOs* | | | | $ | 11,099,491 | | | | | $ | (10,246,763) | | | | | $ | 5,818,159 | | | | | $ | (603,005) | | | | | $ | 25,851 | | | | | $ | 34,783 | | | | | $ | 0 | | | ||
2020 2020 2020 | | | PEO 1 | | | | $ | 12,478,770 | | | | | $ | (11,835,900) | | | | | $ | 50,961,367 | | | | | $ | 0 | | | | | $ | 0 | | | | | $ | 0 | | | | | $ | 0 | | |
| PEO 2 | | | | $ | 1,717,050 | | | | | $ | (551,250) | | | | | $ | 3,891,000 | | | | | $ | 592,015 | | | | | $ | 1,945,500 | | | | | $ | 1,061,203 | | | | | $ | (257,000) | | | ||
| Non-PEO NEOs* | | | | $ | 1,855,694 | | | | | $ | (1,535,473) | | | | | $ | 4,481,588 | | | | | $ | 138,827 | | | | | $ | 0 | | | | | $ | (8,737) | | | | | $ | (182,732) | | |
| Most Important Financial Performance Measures | |
| Revenue | |
| Non-GAAP Gross Margin | |
| Adjusted EBITDA | |
Plan category | | Number of Securities To Be Issued Upon Exercise of Outstanding Options, Warrants and Rights (a) (#) | | Weighted Average Exercise Price of Outstanding Options, Warrants and Rights ($)(1) | | Number of Securities Remaining Available For Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected In Column (a)) (#) | | | Number of Securities To Be Issued Upon Exercise of Outstanding Options, Warrants and Rights (a) (#) | | Weighted Average Exercise Price of Outstanding Options, Warrants and Rights ($)(1) | | Number of Securities Remaining Available For Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected In Column (a)) (#) | | ||||||||||||||||||||||||
Equity compensation plans approved by security holders (2) | | | | 15,413,037(3) | | | | | 4.25 | | | | | 14,284,782 | | | | | | 18,519,495(3) | | | | | 8.03 | | | | | 28,109,043 | | | ||||||
Equity compensation plans not approved by security holders(4 ) | | | | 4,439,618 | | | | | 16.73 | | | | | 1,640,870 | | | ||||||||||||||||||||||
Equity compensation plans not approved by security holders (4) | | | | 4,891,855 | | | | | 20.59 | | | | | 738,731 | | | ||||||||||||||||||||||
Total equity compensation plans | | | | 19,852,655 | | | | | 7.04 | | | | | 15,925,652 | | | | | | 23,411,350 | | | | | 10.50 | | | | | 28,847,774 | | |
| Gross profit | | | | $ | 49,035 | | |
| Amortization of intangible assets | | | | | 733 | | |
| Non-GAAP gross profit | | | | $ | 49,768 | | |
| Net (loss) income | | | | $ | (314,248) | | |
| Interest expense on borrowings | | | | | 14,690 | | |
| Depreciation | | | | | 9,480 | | |
| Amortization of intangible assets | | | | | 913 | | |
| Share-based compensation | | | | | 78,613 | | |
| Change in fair value of contingent consideration | | | | | 2,377 | | |
| Other income, net | | | | | (7,638) | | |
| Adjusted EBITDA | | | | $ | (215,813) | | |